Press Releases

MAYAGUEZ, Puerto Rico and BALTIMORE, Feb. 4, 2020 /PRNewswire/ -- CDI Laboratories, Inc. Antygen Division announced the addition of two powerful new assays to its biomarker discovery platform.  HuScan and VirScan are the first commercial use of PhIP-seq technology developed in the laboratories of Steve Elledg

TARRYTOWN, N.Y., Feb. 4, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, 2019-nCoV, which was recently declared a global public health emergency by the World Health Organization. Rege

BOSTON, Feb. 4, 2020 /PRNewswire/ -- Koura (previously known as Mexichem Fluor), a pioneer in the development of next generation propellants, today announced FDA approval to proceed to clinical trials with Zephex® 152a. This new medical propellant has been under development for several years for use in metered-dose inhalers (MDIs) for treatment of respiratory d

HAMPTON, N.H., Feb. 4, 2020 /PRNewswire/ -- Planet Fitness, Inc., one of the largest and fastest-growing global franchisors and operators of fitness centers with more members tha

MARLBOROUGH, Mass., Feb. 4, 2020 /PRNewswire/ -- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib),

BOSTON, Feb. 4, 2020 /PRNewswire/ -- Atrius Health, New England's largest nonprofit independent medical group, and

NETANYA, Israel, Feb. 4, 2020 /PRNewswire/ -- Sorrel Medical (sorrelmedical.com), a developer and manufacturer of wearable drug delivery devices, today announced the appointment of Bentsi Algazi as Vice President of Operations to meet growing interest in its award-winning wearable self-injection

CARMIEL, Israel, Feb. 4, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will atte

LOS ANGELES, Feb. 4, 2020 /PRNewswire/ -- Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors. To-date, the trial has accrued patients across tumor types.

LOS ANGELES, Feb. 4, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided updated clinical and regulatory guidance on arimoclomol milestones through 2021 in its fo